Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wave Life Sciences (WVE) and Acurx Pharmaceuticals (...

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE), BrightSpring Health Servic...

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Wave Life Sciences, with a price target of $15.00. Issi cover...

Wave Life Sciences (WVE) Receives a Buy from RBC Capital

In a report released today, from B. Riley Securities reiterated a Buy rating on Wave Life Sciences, with a price target of $22.00. Currently, the a...

B. Riley Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Truist Financial analyst Danielle Brill maintained a Buy rating on Wave Life Sciences today and set a price target of $15.00. According to TipRanks...

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Wedbush analyst Yun Zhong assigned a Buy rating to Wave Life Sciences today and set a price target of $12.00. According to TipRanks, Zhong is an an...

Wedbush Releases a Buy Rating on Wave Life Sciences (WVE)

The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sciences reported second-quarter 2026 results on July 30, 2026, alongs...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	WVE	$5.41	0.00%	6.06M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	WVE	$5.41	0%	6.06M
3
4
5
6

WVE

Get Wave Life Sciences Ltd. Data in Excel

Get Wave Life Sciences Ltd. Data in Excel